Article thumbnail

Hyperglycemia-Induced Platelet Activation in Type 2 Diabetes Is Resistant to Aspirin but Not to a Nitric Oxide–Donating Agent

By Paolo Gresele, Stefania Marzotti, Giuseppe Guglielmini, Stefania Momi, Silvia Giannini, Pietro Minuz, Paola Lucidi and Geremia B. Bolli
Topics: Original Research
Publisher: American Diabetes Association
OAI identifier: oai:pubmedcentral.nih.gov:2875435
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. Acute, short-termhyperglycemiaenhancesshear stress–induced platelet activation in patients with type II diabetes mellitus.
  2. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J.
  3. (1998). BoneuB,CadroyY.Anewmethodforquantifying platelet deposition in flowing native blood in an ex vivo model of human thrombogenesis. Thromb Haemost
  4. (2004). Chemiluminescence and LC-MS/MS analyses for the study of nitric oxide release and distribution following oral administration of nitroaspirin (NCX 4016) in healthy volunteers.
  5. (2007). De MonteP,BonizzoniE.PreventionbyNCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication. Thromb Haemost
  6. Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX4016).JPharmacolExpTher2005;
  7. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials.
  8. (2007). Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
  9. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs.
  10. (2003). Nesto RW. The platelets in diabetes: focus on prevention of ischemic events. Diabetes Care
  11. (2002). Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res
  12. (1992). Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation
  13. Pharmacodynamic hybrids coupling established cardiovascular mechanisms of action with additional nitric oxide releasing properties.
  14. (2006). Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders. Cardiovasc Drug Rev
  15. Platelet activation in type 2 diabetes mellitus.
  16. Platelets are essential for leukocyte recruitment in allergic inflammation.
  17. Platelets release active matrix metalloproteinase-2 in vivo in humans at a site of vascular injury: lack of inhibition by aspirin.
  18. (2005). Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes
  19. (1996). Reduced effect of aspirin on thrombus formation at high shear and disturbed laminar blood flow. Thromb Haemost
  20. (2008). Resistance to aspirin and thienopyridines in diabetes mellitus and metabolic syndrome. Curr Vasc Pharmacol
  21. (2008). Searching for new NO-donor aspirin-like molecules: a new class of nitrooxy-acyl derivatives of salicylic acid.
  22. Shear stress activation of platelet glycoprotein IIb/IIIa plus von Willebrand factor causes aggregation: filter blockage and the long bleeding time in von Willebrand’s disease.
  23. The nitric oxide-donating derivative of acetylsalicylic acid, NCX 4016, stimulates glucose transport and glucose transporters translocation in 3T3–L1 adipocytes
  24. (1999). The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care
  25. Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: the Framingham offspring study.